BOSTON and LAUSANNE,
Switzerland, June 9, 2022 /PRNewswire/ -- SOPHiA GENETICS
(Nasdaq: SOPH), the Institut d'Investigacions Biomèdiques August Pi
i Sunyer (IDIBAPS) of Barcelona,
and the Spanish Diagnóstica Longwood today announced from the
European Hematology Association Congress in Vienna that they have combined their expertise
to develop a new Chronic Lymphocytic Leukemia (CLL) solution to
advance CLL care. This collaboration will unify the wide variety of
current guideline recommendations into one single application
aiming to improve CLL characterization and CLL research practices
in Iberia.
![(PRNewsfoto/SOPHiA GENETICS) (PRNewsfoto/SOPHiA GENETICS)](https://mma.prnewswire.com/media/1835876/SOPHiA_GENETICS_Logo.jpg)
SOPHiA GENETICS has already facilitated the analysis of one
million genomic profiles through the SOPHiA DDM™ Platform,
including a significant amount of onco-hematological-related
diseases such as acute myeloid leukemia and lymphomas. The Platform
computes a wide array of genomic variants needed to continually
hone machine learning algorithms designed to accurately detect rare
and challenging cases. The growing number of users of the
SOPHiA DDM™ community can share and access insights by pulling the
relevant signals detected from the noise, ultimately saving time
and helping to make better-informed decisions.
The new CLL solution allows for progress of Chronic Lymphocytic
Leukemia research using genomic analysis. This could lead to better
detection of the disease, which accounts for 25-30% of all leukemia
cases in Western countries and affects yearly more than 100,000
people globally[1], and ultimately improve patient care. Thanks to
the SOPHiA DDM™ Platform and IDIBAPS, hematopathologists can now
access guidelines for the mutational status of TP53,
immunoglobulin (IG) gene rearrangements and their somatic
hypermutation status, while benefitting from the identification of
23 CLL-specific genes for SNVs, InDels and CNVs including
NOTCH1, SF3B1, ATM, IGLV3-21, BTK,
PLCG2, BCL2, del13q14, and trisomy 12, all in one
single NGS workflow.
The new CLL solution has already been used in routine in
Spain, with further opportunities
throughout the country, and in Latin
America through Diagnóstica Longwood's distribution
channels.
"We are proud to work together with some of the most renowned
experts in the field of Chronic Lymphocytic Leukemia research
around the world. This partnership is a great example of how
combining advanced data analytics with emerging CLL strategies can
move the possibilities of data-driven medicine forward," said
Lara Hashimoto, Chief Business
Officer at SOPHiA GENETICS.
"It is a great satisfaction to see how thanks to the partnership
with SOPHiA GENETICS and Diagnóstica Longwood we will be able to
transfer into clinical practice the relevant information generated
for so many years in the research of CLL using a simple and robust
assay," said Elías Campo, principal investigator and director of
IDIBAPS.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a healthcare technology
company dedicated to establishing the practice of data-driven
medicine as the standard of care and for life sciences research. It
is the creator of the SOPHiA DDM™ Platform, a cloud-based SaaS
platform capable of analyzing data and generating insights from
complex multimodal data sets and different diagnostic modalities.
The SOPHiA DDM™ Platform and related solutions, products and
services are currently used by more than 790 hospital, laboratory,
and biopharma institutions globally. For more information,
visit SOPHiAGENETICS.COM, or connect on Twitter, LinkedIn and
Instagram. Where others see data, we see answers.
About IDIBAPS
The August Pi i Sunyer Biomedical Research Institute (IDIBAPS)
is a biomedical research center of excellence that addresses the
most common diseases in our environment. It is a public consortium
comprising the Catalan Government (Generalitat de Catalunya), the
Hospital Clínic Barcelona, the
Faculty of Medicine and Health Sciences at the University of Barcelona and the CSIC Institute of
Biomedical Research of Barcelona.
About 1,500 professionals are organized in a hundred research
groups. IDIBAPS undertakes translational research. It focuses on
ensuring that the questions that arise at the patient's bedside
have a response in the laboratory, and that advances made in the
laboratory are promptly applied to patients. With over 1,200
articles published annually, it is the leading biomedical research
center in Spain.
About Diagnóstica Longwood S.L.
Diagnóstica Longwood is a Spanish company founded 30 years ago
with the aim of satisfying the needs of the laboratory
professional, over the years specializing in molecular diagnostics.
Through innovation, continuous improvement and ongoing commitment
to the integration of new technologies, the company has become a
leader distributor company in Transplant Immunology, Genetics,
Hematology, Oncology and blood banks among others offering its
clients an integrated, personalized and efficient service. Thanks
to the dynamic, versatile and highly qualified human resources at
Diagnóstica Longwood, it is able to complete the puzzle of business
excellence, which enables the professional to optimize the entire
process and obtain the best results. Its catalogue of products
includes leading brands for molecular diagnostics such as SOPHiA
GENETICS.
The Diagnóstica Longwood stands out for its great team of highly
qualified professionals, who respond quickly and efficiently to the
needs of the customers, both in the national territory and abroad.
This personalized attention is part of the DNA of the team and one
of the strategic values of the company.
For more information, visit DLONGWOOD.COM, or connect on
LinkedIn.
SOPHiA GENETICS products are for Research Use Only and not
for use in diagnostic procedures, unless specified otherwise. The
information in this press release is about products that may or may
not be available in different countries and, if applicable, may or
may not have received approval or market clearance by a
governmental regulatory body for different indications for use.
Please contact support@sophiagenetics.com to obtain the
appropriate product information for your country of
residence.
SOPHiA GENETICS Forward-Looking Statements:
This press release contains statements that constitute
forward-looking statements. All statements other than statements of
historical facts contained in this press release, including
statements regarding SOPHiA GENETICS' future results of operations
and financial position, business strategy, products and technology,
as well as plans and objectives of management for future
operations, are forward-looking statements. Forward-looking
statements are based on SOPHiA GENETICS' management's beliefs and
assumptions and on information currently available to its
management. Such statements are subject to risks and uncertainties,
and actual results may differ materially from those expressed or
implied in the forward-looking statements due to various factors,
including those described in SOPHiA GENETICS' filings with the U.S.
Securities and Exchange Commission. No assurance can be given that
such future results will be achieved. Such forward-looking
statements contained in this press release speak only as of the
date hereof. SOPHiA GENETICS expressly disclaims any obligation or
undertaking to update these forward-looking statements contained in
this press release to reflect any change in its expectations or any
change in events, conditions, or circumstances on which such
statements are based, unless required to do so by applicable law.
No representations or warranties (expressed or implied) are made
about the accuracy of any such forward-looking statements.
[1] 1. Siegel RL, Miller KD, Goding Sauer A, Fedewa SA,
Butterly LF, Anderson JC, et al. Colorectal cancer statistics,
2020. CA Cancer J Clin. 2020;70:145–164. doi:
10.3322/caac.21601.
Media Contact:
Sophie
Reymond
+41 79 863 11 10
sreymond@sophiagenetics.com
Logo
- https://mma.prnewswire.com/media/1835876/SOPHiA_GENETICS_Logo.jpg